metformin has been researched along with Anorexia in 6 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Anorexia: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "7%) stopped metformin therapy due to excessive anorexia." | 7.74 | Treatment of white coat hypertension with metformin. ( Camci, C; Helvaci, MR; Sevinc, A; Yalcin, A, 2008) |
| "Liraglutide provided better glycaemic control and greater body weight reduction than sitagliptin when administered as add-on to metformin." | 5.22 | Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial. ( Bian, F; Bosch-Traberg, H; Geng, J; Li, Y; Liu, J; Liu, Y; Luo, Y; Lv, X; Mu, Y; Peng, Y; Sun, Y; Yang, J; Zang, L, 2016) |
| "Metformin reduces body weight by decreasing food intake in humans and animals." | 3.83 | The effect of metformin on neuronal activity in the appetite-regulating brain regions of mice fed a high-fat diet during an anorectic period. ( Choi, SH; Jin, BY; Kim, DH; Kim, HJ; Oh, MJ; Shin, KH, 2016) |
| "7%) stopped metformin therapy due to excessive anorexia." | 3.74 | Treatment of white coat hypertension with metformin. ( Camci, C; Helvaci, MR; Sevinc, A; Yalcin, A, 2008) |
| "The pathogenesis of cancer anorexia is multifactorial and associated with disturbances of the central physiological mechanisms controlling food intake." | 1.34 | A central role for neuronal adenosine 5'-monophosphate-activated protein kinase in cancer-induced anorexia. ( Carvalheira, JB; de Souza, CT; Faria, MC; Morari, J; Pauli, JR; Ropelle, ER; Saad, MJ; Ueno, M; Velloso, LA; Zecchin, KG, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, HJ | 1 |
| Jin, BY | 1 |
| Oh, MJ | 1 |
| Shin, KH | 1 |
| Choi, SH | 1 |
| Kim, DH | 1 |
| Zang, L | 1 |
| Liu, Y | 1 |
| Geng, J | 1 |
| Luo, Y | 1 |
| Bian, F | 1 |
| Lv, X | 1 |
| Yang, J | 1 |
| Liu, J | 1 |
| Peng, Y | 1 |
| Li, Y | 1 |
| Sun, Y | 1 |
| Bosch-Traberg, H | 1 |
| Mu, Y | 1 |
| Helvaci, MR | 1 |
| Sevinc, A | 1 |
| Camci, C | 1 |
| Yalcin, A | 1 |
| Wong, LL | 1 |
| Wong, TC | 1 |
| Ropelle, ER | 1 |
| Pauli, JR | 1 |
| Zecchin, KG | 1 |
| Ueno, M | 1 |
| de Souza, CT | 1 |
| Morari, J | 1 |
| Faria, MC | 1 |
| Velloso, LA | 1 |
| Saad, MJ | 1 |
| Carvalheira, JB | 1 |
| Linder, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes.(LIRA-DPP-4 CHINA™)[NCT02008682] | Phase 4 | 368 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change from baseline in mean of 7-point self-measured plasma glucose at week 26. The 7-point self-measured plasma glucose levels were measured before and after (120 minutes after the start of the meal) the three main meals (breakfast, lunch and dinner), and at bed time. (NCT02008682)
Timeframe: Week 0, week 26
| Intervention | mmol/L (Mean) |
|---|---|
| Liraglutide | -2.25 |
| Sitagliptin | -1.36 |
Mean change from baseline in fasting plasma glucose (FPG) at Week 26. (NCT02008682)
Timeframe: Week 0, week 26
| Intervention | mmol/L (Mean) |
|---|---|
| Liraglutide | -2.347 |
| Sitagliptin | -1.205 |
Mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 26. (NCT02008682)
Timeframe: Week 0, week 26
| Intervention | Percent (%) glycosylated haemoglobin (Mean) |
|---|---|
| Liraglutide | -1.666 |
| Sitagliptin | -0.969 |
confirmed hypoglycaemic episode defined as severe (unable to treat her/himself) or biochemically confirmed by a plasma glucose < 3.1 mmol/L (NCT02008682)
Timeframe: Weeks 0-26
| Intervention | episodes (Number) |
|---|---|
| Liraglutide | 2 |
| Sitagliptin | 1 |
Calculated as the percentage of subjects achieving treatment target of HbA1c < 7.0% at Week 26 (NCT02008682)
Timeframe: After 26 weeks of treatment
| Intervention | percentage of subjects (Number) |
|---|---|
| Liraglutide | 76.5 |
| Sitagliptin | 52.6 |
Calculated as the percentage of subjects achieving treatment target of HbA1c <= 6.5% at Week 26 (NCT02008682)
Timeframe: After 26 weeks of treatment
| Intervention | percentage of subjects (Number) |
|---|---|
| Liraglutide | 61.7 |
| Sitagliptin | 26.3 |
1 trial available for metformin and Anorexia
| Article | Year |
|---|---|
Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Asian People; Blood Glucose; Body Weight; Chin | 2016 |
5 other studies available for metformin and Anorexia
| Article | Year |
|---|---|
The effect of metformin on neuronal activity in the appetite-regulating brain regions of mice fed a high-fat diet during an anorectic period.
Topics: Analysis of Variance; Animals; Anorexia; Body Weight; Brain; Diet, High-Fat; Eating; Gene Expression | 2016 |
Treatment of white coat hypertension with metformin.
Topics: Adolescent; Adult; Aged; Anorexia; Appetite Depressants; Blood Glucose; Dyslipidemias; Female; Human | 2008 |
Metformin induced anorexia and weight loss.
Topics: Aged; Aged, 80 and over; Anorexia; Female; Humans; Hypoglycemic Agents; Metformin; Weight Loss | 2003 |
A central role for neuronal adenosine 5'-monophosphate-activated protein kinase in cancer-induced anorexia.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Anorexia; Deoxyglucose; Drug Adm | 2007 |
Clinical problem-solving: a square peg in a round hole.
Topics: Anorexia; Humans; Hyperglycemia; Metformin | 1998 |